3,146 research outputs found

    Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

    Get PDF
    BACKGROUND: Parkinson\u27s disease (PD) patients using levodopa commonly develop dyskinesia and OFF episodes that reduce quality of life. OBJECTIVE: Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of GocovriĀ® (amantadine) extended release capsules on these episodes. METHODS: Evaluate diary data from pooled Gocovri phase 3, placebo-controlled trials-analyzed for 17 hours following wake-up-at baseline and week 12. RESULTS: Diaries were evaluable for 162 patients. At baseline, 67% of patients woke up OFF, with prevalence decreasing to 13% at 2 hours and then remaining relatively steady at āˆ¼12% (range, 6-17%) across half-hour intervals thereafter. Troublesome dyskinesia prevalence rose steadily from 5% to 24% over the first 2 hours, then fluctuated between 20% and 44% through the rest of the waking day. At baseline, patients experienced a mean of 3.0 daily episodes of troublesome dyskinesia (average duration 2.0 hours each), and 2.2 daily episodes of OFF (average duration 1.1 hour each). At week 12, Gocovri-treated patients showed greater reductions than placebo in troublesome dyskinesia and OFF episodes per day (treatment difference: -1.0 episodes and -0.4 episodes, respectively) and average episode duration (treatment difference: -0.6 hours and -0.3 hours, respectively). Mean duration of individual episodes of ON without troublesome dyskinesia (Good ON) increased by 5.0 hours for Gocovri, compared with 2.0 hours for placebo. Patients taking Gocovri experienced 2.2 fewer transitions between states than patients taking placebo. CONCLUSIONS: Troublesome dyskinesia and OFF occurred in the morning and throughout the waking day. Gocovri-treated patients experienced fewer, shorter episodes of both troublesome dyskinesia and OFF, thereby increasing the duration of continuous Good ON episodes and reducing the frequency of transitions between motor states

    A Turbine-powered UAV Controls Testbed

    Get PDF
    The latest version of the NASA Flying Controls Testbed (FLiC) integrates commercial-off-the-shelf components including airframe, autopilot, and a small turbine engine to provide a low cost experimental flight controls testbed capable of sustained speeds up to 200 mph. The series of flight tests leading up to the demonstrated performance of the vehicle in sustained, autopiloted 200 mph flight at NASA Wallops Flight Facility's UAV runway in August 2006 will be described. Earlier versions of the FLiC were based on a modified Army target drone, AN/FQM-117B, developed as part of a collaboration between the Aviation Applied Technology Directorate at Fort Eustis, Virginia and NASA Langley Research Center. The newer turbine powered platform (J-FLiC) builds on the successes using the relatively smaller, slower and less expensive unmanned aerial vehicle developed specifically to test highly experimental flight control approaches with the implementation of C-coded experimental controllers. Tracking video was taken during the test flights at Wallops and will be available for presentation at the conference. Analysis of flight data from both remotely piloted and autopiloted flights will be presented. Candidate experimental controllers for implementation will be discussed. It is anticipated that flight testing will resume in Spring 2007 and those results will be included, if possible
    • ā€¦
    corecore